Atezolizumab for Usual Interstitial Pneumonia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Cedars-Sinai Medical Center, Los Angeles, CA
Usual Interstitial Pneumonia+2 More
Atezolizumab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to determine the safety and preliminary efficacy of atezolizumab, an immune checkpoint inhibitor approved for the treatment of various cancers, in patients with idiopathic pulmonary fibrosis (IPF).

Eligible Conditions

  • Usual Interstitial Pneumonia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Usual Interstitial Pneumonia

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 24 weeks

24 weeks
Forced vital capacity
Incidence of Treatment-Emergent Adverse Events
Radiologic extent of fibrosis
Six minute walk distance
St. George's Respiratory Questionnaire
University of California San Diego (UCSD) Shortness of Breath Questionnaire

Trial Safety

Safety Progress

1 of 3

Other trials for Usual Interstitial Pneumonia

Side Effects for

Atezolizumab
27%Fatigue
25%Decreased appetite
24%Cough
19%Asthenia
19%Dyspnoea
18%Constipation
18%Nausea
18%Pyrexia
16%Diarrhoea
13%Arthralgia
12%Vomiting
12%Anaemia
11%Rash
11%Back pain
11%Musculoskeletal pain
10%Headache
9%Oedema peripheral
9%Weight decreased
9%Insomnia
9%Chest pain
9%Pruritus
9%Pain in extremity
8%Dizziness
7%Haemoptysis
7%Aspartate aminotransferase increased
7%Upper respiratory tract infection
7%Myalgia
6%Influenza like illness
6%Alanine aminotransferase increased
6%Bronchitis
6%Nasopharyngitis
6%Productive cough
5%Depression
5%Dry skin
5%Musculoskeletal chest pain
4%Paraesthesia
4%Urinary tract infection
4%Neuropathy peripheral
4%Abdominal pain
3%Stomatitis
3%Pneumonia
3%Dysgeusia
2%Pleural effusion
2%Malaise
2%Neutropenia
1%Respiratory tract infection
1%Pulmonary embolism
1%Peripheral sensory neuropathy
1%Sepsis
1%Pneumonitis
1%Alopecia
1%Mucosal inflammation
1%Bone pain
1%Lacrimation increased
0%Pharyngitis
0%Tachycardia paroxysmal
0%Localised oedema
0%Cholecystitis
0%Stress cardiomyopathy
0%Death
0%Clostridium difficile colitis
0%Febrile infection
0%Systemic inflammatory response syndrome
0%Rhabdomyolysis
0%Cellulitis
0%Prostate cancer
0%Pleural fistula
0%Infection
0%Cardiac failure congestive
0%Neutrophil count decreased
0%Leukoencephalopathy
0%Lumbar vertebral fracture
0%Haematuria
0%Gastrointestinal infection
0%Burns third degree
0%Haematoma
0%Organising pneumonia
0%Pneumonia aspiration
0%Nail disorder
0%Basal cell carcinoma
0%Pruritus generalised
0%Depressed level of consciousness
0%Appendicitis
0%Hypersensitivity
0%Supraventricular tachycardia
0%Oesophageal obstruction
0%Pulmonary sepsis
0%Spinal compression fracture
0%Muscular weakness
0%Gastrointestinal fungal infection
0%Pericarditis
0%Retinopathy
0%Melaena
0%Hepatitis
0%Generalised oedema
0%Pancreatitis
0%Clostridium difficile infection
0%Gastroenteritis
0%Dehydration
0%Pneumocystis jirovecii pneumonia
0%Paronychia
0%Hemiparesis
0%White blood cell count decreased
0%Seizure
0%Small intestinal obstruction
0%Femoral neck fracture
0%Oesophageal varices haemorrhage
0%Fracture displacement
0%Pyelonephritis
0%Pulmonary haemorrhage
0%Cerebral thrombosis
0%Emphysema
0%Acute hepatic failure
0%Device related infection
0%Haemorrhage intracranial
0%Neutropenic sepsis
0%Pleuritic pain
0%Myocardial ischaemia
0%Myocardial infarction
0%Duodenal perforation
0%Colon cancer
0%Generalised tonic-clonic seizure
0%Upper gastrointestinal haemorrhage
0%Gastritis erosive
0%Lower gastrointestinal haemorrhage
0%Cholecystitis acute
0%General physical health deterioration
0%Sudden death
0%Henoch-Schonlein purpura nephritis
0%Confusional state
0%Haematochezia
0%Infected skin ulcer
0%Overdose
0%Colitis
0%Localised infection
0%Gastroenteritis viral
0%Faeces discoloured
0%Hypotension
0%Cerebral artery embolism
0%Syncope
0%Acute kidney injury
0%Radius fracture
0%Cerebrovascular accident
0%Pericardial effusion
0%Post procedural haematuria
0%Aphasia
0%Encephalopathy
0%Guillain-Barre syndrome
0%Neuralgia
0%Oesophageal fistula
0%Left ventricular dysfunction
0%Abdominal pain lower
0%Abdominal pain upper
0%Dysphagia
0%Chest discomfort
0%Neck pain
0%Abdominal sepsis
0%Sciatica
0%Hepatitis acute
0%Bacterial sepsis
0%Diverticulitis
0%Meningitis
0%Parotitis
0%Upper limb fracture
0%Neoplasm malignant
0%Hypoxia
0%Interstitial lung disease
0%Thrombosis
0%Deep vein thrombosis
0%Superior vena cava syndrome
0%Ankle fracture
0%Mental status change
0%Intestinal obstruction
0%Tachycardia
0%Drug-induced liver injury
0%Pneumothorax
0%Pneumonia bacterial
0%Pain
0%Subileus
0%Pseudomembranous colitis
0%Fall
0%Pleural infection
0%Bronchospasm
0%Pneumothorax spontaneous
0%Chronic obstructive pulmonary disease
0%Urosepsis
0%Cancer pain
0%Benign prostatic hyperplasia
0%Febrile neutropenia
0%Leukocytosis
0%Acute myocardial infarction
0%Angina pectoris
0%Arrhythmia
0%Atrial fibrillation
0%Atrial flutter
0%Cardiac arrest
0%Cardiac tamponade
0%Encephalitis
0%Enteritis infectious
0%Infectious pleural effusion
0%Infective exacerbation of chronic obstructive airways disease
0%Influenza
0%Lower respiratory tract infection
0%Lung infection
0%Septic shock
0%Skin infection
0%Tonsillitis
0%Upper respiratory tract infection bacterial
0%Hip fracture
0%Humerus fracture
0%Infusion related reaction
0%Failure to thrive
0%Hypercalcaemia
0%Hyperglycaemia
0%Hypoglycaemia
0%Hypokalaemia
0%Hyponatraemia
0%Cognitive disorder
0%Renal failure
0%Acute respiratory distress syndrome
0%Acute respiratory failure
0%Aspiration
0%Atelectasis
0%Bronchial obstruction
0%Pulmonary oedema
0%Respiratory distress
0%Respiratory failure
0%Tachypnoea
0%Pemphigoid
This histogram enumerates side effects from a completed 2019 Phase 3 trial (NCT02008227) in the Atezolizumab ARM group. Side effects include: Fatigue with 27%, Decreased appetite with 25%, Cough with 24%, Asthenia with 19%, Dyspnoea with 19%.

Trial Design

1 Treatment Group

Atezolizumab
1 of 1
Experimental Treatment

24 Total Participants · 1 Treatment Group

Primary Treatment: Atezolizumab · No Placebo Group · Phase 1

Atezolizumab
Drug
Experimental Group · 1 Intervention: Atezolizumab · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atezolizumab
2015
Completed Phase 4
~6340

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 24 weeks
Closest Location: Cedars-Sinai Medical Center · Los Angeles, CA
Photo of Los Angeles 1Photo of Los Angeles 2Photo of Los Angeles 3
2006First Recorded Clinical Trial
0 TrialsResearching Usual Interstitial Pneumonia
515 CompletedClinical Trials

Who is running the clinical trial?

Genentech, Inc.Industry Sponsor
1,482 Previous Clinical Trials
563,321 Total Patients Enrolled
Cedars-Sinai Medical CenterLead Sponsor
449 Previous Clinical Trials
144,297 Total Patients Enrolled
Tanzira Zaman, MDPrincipal InvestigatorCedars-Sinai Medical Center
Alain Mita, MDPrincipal InvestigatorCedars-Sinai Medical Center
3 Previous Clinical Trials
123 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a positive pregnancy test if you are male or female, respectively, ≥50 years of age.
Subjects must have a high-resolution computed tomography (HRCT) completed in the 6 months prior to informed consent.
You have a lung disease with fibrotic changes on HRCT.
You have a positive total hepatitis B core antibody (HBcAb) test, or a positive total hepatitis B core antibody (HBcAb) test followed by a negative hepatitis B virus (HBV) DNA test at screening.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.